Skip to Main Content

Advertisement

Umbrella Alt Text
header search
Search
Advanced Search
Skip Nav Destination

Precision Medicine and Biomarkers

Clinical or translational studies aimed at optimally matching patients to treatments, including biomarkers and resistance mechanisms

SUBMIT TO JOURNAL
Latest in Precision Medicine and Biomarkers
May 31 2023
Desmoplastic reaction associates with prognosis and adjuvant chemotherapy response in colorectal cancer: a multicenter retrospective study
Qingru Hu, Yiting Wang et al.
Desmoplastic reaction (DR) is one of many tumor-host interactions and is associated with the overall survival (OS) of patients with colorectal cancer (CRC). However, the clinical significance of DR requires further study in large multicenter cohorts and its predictive value in adjuvant chemotherapy (ACT) response remains ...
May 30 2023
Enhanced Detection of Landmark Minimal Residual Disease in Lung Cancer Using Cell-free DNA Fragmentomics
Siwei Wang, Zhijun Xia et al.
Currently, approximately 30%–55% of the patients with non–small cell lung cancer (NSCLC) develop recurrence due to minimal residual disease (MRD) after receiving surgical resection of the tumor. This study aims to develop an ultrasensitive and affordable fragmentomic assay for MRD detection in patients with NSCLC. A total ...
May 22 2023
EGFR Inhibition by Cetuximab Modulates Hypoxia and IFN Response Genes in Head and Neck Squamous Cell Carcinoma
Ritu Chaudhary, Robbert J.C. Slebos et al.
Head and neck squamous cell carcinoma (HNSCC) has one of the most hypoxic and immunosuppressive tumor microenvironments (TME) among solid tumors. However, there is no proven therapeutic strategy to remodel the TME to be less hypoxic and proinflammatory. In this study, we classified tumors according to a Hypoxia-Immune ...
May 18 2023
Deconstructing olfactory epithelium developmental pathways in olfactory neuroblastoma
John B Finlay, Ralph Abi Hachem et al.
Olfactory neuroblastoma is a rare tumor arising from the olfactory cleft region of the nasal cavity. Due to the low incidence of this tumor, as well as an absence of established cell lines and murine models, understanding the mechanisms driving olfactory neuroblastoma pathobiology has been challenging. Here, we sought to ...
May 18 2023
Chemokine Analysis in Patients with Metastatic Uveal Melanoma Suggests a Role for CCL21 Signaling in Combined Epigenetic Therapy and Checkpoint Immunotherapy
Vasu R. Sah, Henrik Jespersen et al.
Patients with metastatic uveal melanoma have limited therapeutic options and high mortality rate so new treatment options are needed.
May 01 2023
Multiple Germline Events Contribute to Cancer Development in Patients with Li-Fraumeni Syndrome
Vallijah Subasri, Nicholas Light et al.
Li-Fraumeni syndrome (LFS) is an autosomal dominant cancer-predisposition disorder. Approximately 70% of individuals who fit the clinical definition of LFS harbor a pathogenic germline variant in the TP53 tumor suppressor gene. However, the remaining 30% of patients lack a TP53 variant and even among variant TP53 ...
April 26 2023
Mitochondrial Metabolism Drives Low-density Lipoprotein-induced Breast Cancer Cell Migration
Sandrina Nóbrega-Pereira, Francisco Santos et al.
Most cancer-related deaths are due to metastases. Systemic factors, such as lipid-enriched environments [as low-density lipoprotein (LDL)-cholesterol], favor breast cancer, including triple-negative breast cancer (TNBC) metastasis formation. Mitochondria metabolism impacts TNBC invasive behavior but its involvement in a ...
April 25 2023
CD142 Identifies Neoplastic Desmoid Tumor Cells, Uncovering Interactions Between Neoplastic and Stromal Cells That Drive Proliferation
Mushriq Al-Jazrawe, Steven Xu et al.
The interaction between neoplastic and stromal cells within a tumor mass plays an important role in cancer biology. However, it is challenging to distinguish between tumor and stromal cells in mesenchymal tumors because lineage-specific cell surface markers typically used in other cancers do not distinguish between the ...
April 20 2023
Systemic LRG1 Expression in Melanoma is Associated with Disease Progression and Recurrence
Esmee P. Hoefsmit, Franziska Völlmy et al.
The response rates upon neoadjuvant immune checkpoint blockade (ICB) in stage III melanoma are higher as compared with stage IV disease. Given that successful ICB depends on systemic immune response, we hypothesized that systemic immune suppression might be a mechanism responsible for lower response rates in late-stage ...
April 11 2023
Digital Spatial Profiling Links Beta-2-microglobulin Expression with Immune Checkpoint Blockade Outcomes in Head and Neck Squamous Cell Carcinoma
Niki Gavrielatou, Ioannis Vathiotis et al.
Programmed cell death protein‐1 (PD-1)-targeted immunotherapy is approved for recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) treatment. Although its efficacy correlates with PD-L1 expression, response is limited even among positive cases. We employed digital spatial profiling (DSP) to discover ...
View all Precision Medicine and Biomarkers articles

Topics in Precision Medicine and Biomarkers

AACR Journals

 

 

  • Copyright © 2022 by the American Association for Cancer Research.
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal
This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy.
Accept